Ladenburg Thalmann Initiates Coverage on Viveve Medical Inc (VIVE)
Separately, Maxim Group reaffirmed a “buy” rating and set a $11.00 target price (down from $16.00) on shares of Viveve Medical in a research report on Tuesday, June 21st.
Shares of Viveve Medical (NASDAQ:VIVE) opened at 7.00 on Tuesday. The company’s market cap is $74.24 million. The company’s 50-day moving average price is $7.58 and its 200 day moving average price is $6.60. Viveve Medical has a 52 week low of $4.02 and a 52 week high of $10.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/ladenburg-thalmann-initiates-coverage-on-viveve-medical-inc-vive.html
Viveve Medical (NASDAQ:VIVE) last announced its earnings results on Thursday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.18. The company earned $1.56 million during the quarter, compared to the consensus estimate of $1.33 million. Equities research analysts anticipate that Viveve Medical will post ($2.06) earnings per share for the current fiscal year.
About Viveve Medical
Viveve Medical, Inc, formerly PLC Systems, Inc, designs, develops, manufactures and markets medical devices for the non-invasive treatment of vaginal laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office.
Receive News & Ratings for Viveve Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.